The United States is increasingly wielding its vast consumer market as a weapon, using the threat of tariffs to compel foreign companies to make significant investment commitments on American soil. The latest tariff proposals are a masterclass in this strategy, turning trade policy into a powerful tool for attracting foreign direct investment (FDI).
The logic is simple and coercive: gain preferential access to the US market by building factories and creating jobs in America. The 100% tariff threatened on pharmaceuticals is the clearest example. Companies like Roche and Novartis, which are already investing heavily in US facilities, have been given strong signals that they will be safe. The unspoken threat to companies that haven’t made similar commitments is clear.
This weaponization of investment fundamentally changes the calculus for international corporations. The decision of where to locate a new factory is no longer just about labor costs or logistics; it’s now a critical geopolitical calculation. To avoid punitive tariffs, companies are being pushed to align their corporate strategy with the political goals of the White House.
This strategy has drawn both admiration for its boldness and condemnation for its protectionist nature. Proponents argue it’s a legitimate way to level the playing field and bring back manufacturing jobs. Critics, like the German auto industry, argue it distorts the market, disrupts efficient supply chains, and ultimately leads to higher costs and fewer choices for consumers.
For countries like the UK, this presents a formidable challenge. Its government must now not only negotiate on trade tariffs but also contend with a powerful US policy designed to lure its most successful companies and their manufacturing bases away. It’s a new form of economic warfare where the prize is not just market share, but the physical location of global industry.